Ophthalmic compositions

Use of a sterile ophthalmic composition comprising:

• a) an oily phase comprising castor oil and a medium chain triglyceride,
• b) one or more surfactants and
• c) an aqueous phase,
• wherein the composition has a pH from 5.0 to 9.0 for the manufacture of a medicament for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye (including keratoconjunctivitis sicca, xerophthalmia, xerosis and Sjögren's syndrome), conjunctivitis (including allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, pemphigoid, Stevens-Johnson syndrome, toxic epidermal necrolysis, viral keratoconjunctivitis and limbic keratoconjunctivitis), dermatitis (including contact dermatitis, atopic dermatitis), blepharitis (including chronic anterior blepharitis, chronic posterior blepharitis), entropion (including paralytic entropion, involutional entropion), floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents, keratitis (including Stromal necrotic keratitis, Cogan's syndrome, Mooren's ulcer, neurotrophic keratitis, exposure keratitis, crystalline infectious keratitis, Thygeson's superficial punctate keratitis, filamentary keratitis, recurring corneal epithelial erosions, epithelial dystrophies and Meesmann's dystrophy), episcleritis and uveitis, more particularly in the treatment and/or prevention of dry eye, blepharitis, keratitis such as filamentary keratitis and ulcerous keratitis, conjunctivitis including atopic keratoconjunctivitis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents.

A method for the prevention and/or treatment of an ocular disease selected from the group consisting of dry eye (including keratoconjunctivitis sicca, xerophthalmia, xerosis and Sjögren's syndrome), conjunctivitis (including allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, pemphigoid, Stevens-Johnson syndrome, toxic epidermal necrolysis, viral keratoconjunctivitis and limbic keratoconjunctivitis), dermatitis (including contact dermatitis, atopic dermatitis), blepharitis (including chronic anterior blepharitis, chronic posterior blepharitis), entropion (including paralytic entropion, involutional entropion), floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, conical ulcers induced by physical or chemical agents, keratitis (including Stromal necrotic keratitis, Cogan's syndrome, Mooren's ulcer, neurotrophic keratitis, exposure keratitis, crystalline infectious keratitis, Thygeson's superficial punctate keratitis, filamentary keratitis, recurring corneal epithelial erosions, epithelial dystrophies and Meesmann's dystrophy), episcleritis and uveitis, more particularly in the treatment and/or prevention of dry eye, blepharitis, keratitis such as filamentary keratitis and ulcerous keratitis, conjunctivitis including atopic keratoconjunctivitis, epithelial damage induced by preservatives, epithelial or anterior chamber damage induced by ocular surgery, limbal cell deficiency, corneal ulcers induced by physical or chemical agents by administering to a subject in need thereof an effective amount of a sterile ophthalmic composition comprising a) an oily phase comprising castor oil and a medium chain triglyceride, b) one or more surfactants and c) an aqueous phase wherein the composition has a pH from 5.0 to 9.0.